Eric Schmitt's questions to Incyte Corp (INCY) leadership • Q1 2025
Question
An analyst on behalf of Eric Schmitt asked what proportion of Niktimvo's Q1 sales was due to inventory build and how dropouts were handled in the long-term povorcitinib HS data analysis.
Answer
Executive Mohamad confirmed that 20-30% of Niktimvo's Q1 sales came from inventory, which is expected to stabilize. Executive Steven Stein explained that for the povorcitinib analysis, they used a conservative non-responder imputation (NRI) and will also analyze a modified NRI, which they expect to yield slightly better results.